Jim Cramer Names Medline a Sleeper Compounder After Large IPO
Medline’s late-2025 IPO raised nearly $6.3B, establishing the company as a major distributor of medical-surgical products and home medical devices. Adjusted EBITDA grew 13.4% to $1.06B in 2026 adjusted results, driven by higher net sales and IEEPA tariff refund benefits. After shares surged near $50, they cooled into the mid-30s as Jim Cramer framed the setup for long-term investors.